Abstract
BackgroundIdentification of molecular subgroups and more precise characterization have led to a variety of new targeted therapies in advanced/recurrent endometrial cancer (EC) demonstrating not only response but better overall survival.Modern approachesUntil now chemotherapy with carboplatin/paclitaxel in the first-line setting and monochemotherapy in subsequent lines were options with limited efficacy. Knowledge of molecular subgroups is an opportunity for individualization through targeted therapies. The most established is currently immunotherapy used in second line; however, studies in the first line are already evaluating the impact of these compounds in combination with chemotherapy as well as monotherapy. Further promising approaches that are being evaluated in trials are, for example, antiHER2 (human epidermal growth factor receptor 2) therapy in HER2-positive serous EC, WEE inhibition, antihormonal medication with CDK4/6 inhibitors and antiangiogenetic agents.
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
